Korean J Clin Oncol.  2018 Jun;14(1):15-20. 10.14216/kjco.18003.

Clinicopathological markers associated with recurrence in ductal carcinoma in situ of breast by age group

• Choi Y
• Hwang TS
• Jeong AR
• Na JW
• Kim YY
• Lee JH
• Jung YS
• Choi S
• Kang JM
• Park HK
• Chun YS

• KMID: 2416317
• DOI: http://doi.org/10.14216/kjco.18003

Abstract

PURPOSE
In the present study, factors related to the recurrence of breast ductal carcinoma in situ (DCIS) in Korean patients were identified, and the prognostic factors for each age group were explored.
METHODS
The subjects were 226 patients who were diagnosed with DCIS by histopathologic examination, and the effect of representative prognostic factors that are known already, including estrogen receptor (ER), progesterone receptor (PR) and the human epidermal growth factor receptor 2 (HER2) status, Ki-67 levels, and adjuvant therapy on the recurrence of DCIS was analyzed by using the Cox proportional hazard model.
RESULTS
Among the 226 subjects, 11 patients underwent the recurrence of breast cancer. The average follow-up period was 52.7±23.5 months. The average age of the subjects was 50.6±9.3 years. Among the DCIS patients, the recurrence of breast cancer was significantly higher in the ER negative patients and those who have a Ki-67 level over 20%. However, the PR and HER2 status did not significantly affect breast cancer recurrence. The result also showed that only ER negative was a significant factor before the age of 50 years and that only the Ki-67 level over 20% was a significant factor to the patients 50 years of age or older.
CONCLUSION
DCIS patients should be appropriately treated and managed depending on their age and clinicopathological factors to prevent the recurrence of DCIS.

Keyword

Breast; Ductal carcinoma in situ; Recurrence; Age

MeSH Terms

Breast Neoplasms
Breast*
Carcinoma, Ductal*
Carcinoma, Intraductal, Noninfiltrating*
Estrogens
Follow-Up Studies
Humans
Proportional Hazards Models
Receptor, Epidermal Growth Factor
Receptors, Progesterone
Recurrence*
Estrogens
Receptor, Epidermal Growth Factor
Receptors, Progesterone